{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:36:56Z","timestamp":1787931416336,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022-2-4013"],"award-info":[{"award-number":["2022-2-4013"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-048"],"award-info":[{"award-number":["2022-PUMCH-B-048"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06140-y","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T09:26:29Z","timestamp":1737883589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0341-6098","authenticated-orcid":false,"given":"Ziping","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"issue":"5","key":"6140_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"6","key":"6140_CR2","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","volume":"37","author":"E Terpos","year":"2023","unstructured":"Terpos E, Musto P, Engelhardt M, et al. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2023;37(6):1175\u201385.","journal-title":"Leukemia"},{"issue":"10","key":"6140_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.38961","volume":"5","author":"LR Hammons","year":"2022","unstructured":"Hammons LR, Szabo A, Janardan A, et al. Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma. JAMA Netw Open. 2022;5(10): e2238961.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"6140_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/cas.16001","volume":"115","author":"D Jin","year":"2024","unstructured":"Jin D, He J, Wu W, et al. Outcomes of COVID-19 in multiple myeloma patients treated with daratumumab. Cancer Sci. 2024;115(1):237\u201346.","journal-title":"Cancer Sci"},{"key":"6140_CR5","unstructured":"https:\/\/www.gov.cn\/zhengce\/zhengceku\/2023\/01\/06\/5735343\/files\/5844ce04246b431dbd322d8ba10afb48.pdf. Accessed 5 July 2023."},{"issue":"9","key":"6140_CR6","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324.","journal-title":"Am J Hematol"},{"issue":"4","key":"6140_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005.","journal-title":"Leukemia"},{"issue":"2","key":"6140_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.7150\/ijbs.59272","volume":"18","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Rubin L, Peng T, et al. Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. Int J Biol Sci. 2022;18(2):459\u201372.","journal-title":"Int J Biol Sci"},{"key":"6140_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112420","volume":"145","author":"M Farahani","year":"2022","unstructured":"Farahani M, Niknam Z, Mohammadi Amirabad L, et al. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. Biomed Pharmacother. 2022;145: 112420.","journal-title":"Biomed Pharmacother"},{"issue":"21","key":"6140_CR10","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips RL, Wang Y, Cheon H, et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell. 2022;185(21):3857\u201376.","journal-title":"Cell"},{"issue":"8","key":"6140_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","volume":"41","author":"W Luo","year":"2020","unstructured":"Luo W, Li YX, Jiang LJ, et al. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol Sci. 2020;41(8):531\u201343.","journal-title":"Trends Pharmacol Sci"},{"key":"6140_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cytogfr.2020.06.013","volume":"54","author":"B Goker Bagca","year":"2020","unstructured":"Goker Bagca B, Biray AC. The potential of JAK\/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Cytokine Growth Factor Rev. 2020;54:51\u201362.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"9","key":"6140_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795\u2013807.","journal-title":"N Engl J Med"},{"key":"6140_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107754","volume":"221","author":"C Zhang","year":"2021","unstructured":"Zhang C, Liu J, Wang J, et al. The emerging role of leukemia inhibitory factor in cancer and therapy. Pharmacol Ther. 2021;221: 107754. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107754.","journal-title":"Pharmacol Ther"},{"key":"6140_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","volume":"54","author":"VJ Costela-Ruiz","year":"2020","unstructured":"Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, et al. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62\u201375.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"6140_CR16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12974-018-1326-y","volume":"15","author":"SM Davis","year":"2018","unstructured":"Davis SM, Collier LA, Winford ED, et al. Leukemia inhibitory factor modulates the peripheral immune response in a rat model of emergent large vessel occlusion. J Neuroinflammation. 2018;15(1):288.","journal-title":"J Neuroinflammation"},{"issue":"15","key":"6140_CR17","doi-asserted-by":"publisher","first-page":"1352583","DOI":"10.3389\/fimmu.2024.1352583","volume":"22","author":"A Baranova","year":"2024","unstructured":"Baranova A, Luo J, Fu L, et al. Evaluating the effects of circulating inflammatory proteins as drivers and therapeutic targets for severe COVID-19. Front Immunol. 2024;22(15):1352583.","journal-title":"Front Immunol"},{"key":"6140_CR18","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2020-0340","author":"SM Metcalfe","year":"2020","unstructured":"Metcalfe SM. LIF and the lung\u2019s stem cell niche: is failure to use LIF to protect against COVID-19 a grave omission in managing the pandemic? Future Virol. 2020. https:\/\/doi.org\/10.2217\/fvl-2020-0340.","journal-title":"Future Virol"},{"issue":"1","key":"6140_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13(1):116.","journal-title":"Blood Cancer J"},{"key":"6140_CR20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162440","author":"NJ Bahlis","year":"2022","unstructured":"Bahlis NJ, Tomasson MH, et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study. Blood. 2022. https:\/\/doi.org\/10.1182\/blood-2022-162440.","journal-title":"Blood"},{"key":"6140_CR21","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1016\/S2152-2650(22)00443-8","volume":"22","author":"A Saez","year":"2022","unstructured":"Saez A, Lopez-Mu\u00f1oz N, S\u00e1nchez-Pina JM, et al. P-113: infectious toxicities in patients treated with bispecific antibodies in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22:S97\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06140-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T09:26:35Z","timestamp":1737883595000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06140-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6140"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06140-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Medical Ethics Committee (No. I-23PJ229) at Peking Union Medical College Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}